ES2188011T3 - Agente de contraste para la reproduccion en imagenes de infartos y necrosis. - Google Patents

Agente de contraste para la reproduccion en imagenes de infartos y necrosis.

Info

Publication number
ES2188011T3
ES2188011T3 ES98946346T ES98946346T ES2188011T3 ES 2188011 T3 ES2188011 T3 ES 2188011T3 ES 98946346 T ES98946346 T ES 98946346T ES 98946346 T ES98946346 T ES 98946346T ES 2188011 T3 ES2188011 T3 ES 2188011T3
Authority
ES
Spain
Prior art keywords
necrosis
infartos
reproduction
images
contrast agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98946346T
Other languages
English (en)
Inventor
Johannes Platzek
Ulrich Niedballa
Bernd Raduchel
Wolfgang Ebert
Hanns-Joachim Weinmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2188011T3 publication Critical patent/ES2188011T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos de la fórmula general I **fórmula** en los que q significa un número de 1, 2 ó 3, G es un enlace directo, un grupo SO2 o un grupo CO, K representa un complejo metálico o sus sales con bases orgánicas y/o inorgánicas o con aminoácidos o con amidas de aminoácidos, R es una cadena de hidrocarbilo C4-C30 no ramificada o ramificada, que eventualmente está sustituida con 1-2 grupos amino, 1-2 grupos SO2, 1-5 grupos OH, 1-5 grupos OR1 con R1 en el significado de un grupo alquilo C1-C6, 1 grupo NH-K, 1-3 grupos carboxi, 1-2 anillos alifáticos o 1-3 anillos aromáticos, y que contiene eventualmente 1-6 grupos amido, 1-2 átomos de azufre, 1-6 átomos de oxígeno, 1-2 anillos alifáticos o 1-3 anillos aromáticos, estando los anillos aromáticos eventualmente sustituidos con 1-2 átomos de cloro, 1-2 grupos de ácidos, 1-2 grupos de OR1 o 1-2 grupos alquilo C1-C6.
ES98946346T 1997-09-26 1998-08-17 Agente de contraste para la reproduccion en imagenes de infartos y necrosis. Expired - Lifetime ES2188011T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19744003A DE19744003B4 (de) 1997-09-26 1997-09-26 Kontrastmittel für das Infarkt- und Nekroseimaging

Publications (1)

Publication Number Publication Date
ES2188011T3 true ES2188011T3 (es) 2003-06-16

Family

ID=7844676

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98946346T Expired - Lifetime ES2188011T3 (es) 1997-09-26 1998-08-17 Agente de contraste para la reproduccion en imagenes de infartos y necrosis.

Country Status (12)

Country Link
US (1) US6083479A (es)
EP (1) EP1017684B1 (es)
JP (1) JP2001518471A (es)
AT (1) ATE228116T1 (es)
AU (1) AU9342898A (es)
CA (1) CA2304458A1 (es)
DE (2) DE19744003B4 (es)
DK (1) DK1017684T3 (es)
ES (1) ES2188011T3 (es)
NO (1) NO315514B1 (es)
PT (1) PT1017684E (es)
WO (1) WO1999016757A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
US6649587B1 (en) 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
IL146126A0 (en) * 1999-04-30 2002-07-25 Slil Biomedical Corp Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
DE10002939C1 (de) * 2000-01-13 2001-09-20 Schering Ag Paramagnetische DOTA-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung für die Herstellung von pharmazeutischen Mitteln
US20030072715A1 (en) * 2000-08-02 2003-04-17 Benjamin Frydman Cyclic polyamine compounds for cancer therapy
US7048907B2 (en) * 2001-02-05 2006-05-23 Biophysics Assay Laboratory, Inc. Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products
FR2857967B1 (fr) * 2003-07-25 2015-04-24 Centre Nat Rech Scient Complexes de lanthanide, leur preparation et leurs utilisations
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
JP2008508333A (ja) * 2004-08-05 2008-03-21 ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン 標的分子の改変および組織化のための多価キレーター
DE102005033902B3 (de) * 2005-07-15 2007-04-05 Schering Ag Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel
DE102005033903B4 (de) * 2005-07-15 2007-08-09 Bayer Schering Pharma Ag Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel
DE102006049821A1 (de) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
DE102007058220A1 (de) 2007-12-03 2009-06-04 Bayer Schering Pharma Aktiengesellschaft Dimere macrocyclisch substituierte Benzolderivate
EP2233485A1 (en) * 2009-03-23 2010-09-29 Universität Regensburg Fluorophore-containing compounds and their use in the detection of phosphorylated (poly)peptides
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
WO2018096082A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
AT521001B1 (de) * 2018-02-23 2020-10-15 Sanochemia Pharmazeutika Ag Herstellungsverfahren für ein Kontrastmittel
BR112021007707A2 (pt) 2018-11-23 2021-07-27 Bayer Aktiengesellschaft formulação de meios de contraste e processo de preparação da mesma
CN109602920B (zh) * 2019-01-18 2021-06-29 厦门大学 一类树枝状分子影像探针及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
US5756065A (en) * 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
GB9320277D0 (en) * 1993-10-01 1993-11-17 Nycomed Salutar Inc Chelants
US5650133A (en) * 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
US5446145A (en) * 1990-01-19 1995-08-29 Nycomed Salutar, Inc. Polychelant compounds
US5972307A (en) * 1989-10-23 1999-10-26 Nycomed Salutar, Inc. Dichelants
DE3938992A1 (de) * 1989-11-21 1991-05-23 Schering Ag Kaskadenpolymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4035760A1 (de) * 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
GB9318550D0 (en) * 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
DE4425857A1 (de) * 1994-07-07 1996-01-11 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zur ihrer Herstellung und diese enthaltende pharmazeutische Mittel
DE19549286A1 (de) * 1995-12-22 1997-06-26 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US5874061A (en) * 1995-12-22 1999-02-23 Schering Aktiengesellschaft Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes

Also Published As

Publication number Publication date
US6083479A (en) 2000-07-04
JP2001518471A (ja) 2001-10-16
EP1017684B1 (de) 2002-11-20
DE59806371D1 (de) 2003-01-02
EP1017684A1 (de) 2000-07-12
PT1017684E (pt) 2003-03-31
WO1999016757A1 (de) 1999-04-08
DK1017684T3 (da) 2003-03-03
CA2304458A1 (en) 1999-04-08
DE19744003B4 (de) 2004-07-08
ATE228116T1 (de) 2002-12-15
NO20001556D0 (no) 2000-03-24
NO315514B1 (no) 2003-09-15
AU9342898A (en) 1999-04-23
NO20001556L (no) 2000-05-23
DE19744003A1 (de) 1999-07-15

Similar Documents

Publication Publication Date Title
ES2188011T3 (es) Agente de contraste para la reproduccion en imagenes de infartos y necrosis.
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
FR2764887B1 (fr) Melange de diphenylamines nonylees, procede pour le preparer et composition le contenant
AR012717A1 (es) Trihidrato de la sal de magnesio de s-omeprazol, proceso para su preparacion, composicion farmaceutica, y uso de dicho trihidrato para la fabricacion de medicamentos.
RU94042393A (ru) Галихондрины, родственные соединения и способ лечения опухоли у млекопитающих
MA26494A1 (fr) Inhibiteurs de proteases nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26499A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
ZA965752B (en) Triphenylethylenes, process for their production, pharmaceutical preparations that contain these triphenylethylenes as well as their use for the production of pharmaceutical agents.
PT741716E (pt) Analogos de delta 12,13-iso-taxol sua utilizacao anti-neoplasica e composicoes farmaceuticas que os contem
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
MA26523A1 (fr) Modification thermodynamiquement stable de 1-(4-carbazolyloxy)-3-(2-(2-methoxyphenoxy) ethylamino)-2-propanole, procede pour sa preparation et compositions pharmaceutiques le comprenant
AU6200599A (en) Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of acomposition for the treatment of ischemic stroke
MA26487A1 (fr) Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant .
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
MA25418A1 (fr) Procede pour produire des preparations pharmaceutiques solides rapidement decomposables.
BG101867A (en) Benzothiazenedioxides as endothelin antagonists
MA26538A1 (fr) 2-aminopyridines alkoxy-substituees nouvelle, compositions pharmaceutiques les contenant et procede pour leur preparation.
SE9802937D0 (sv) Novel compounds
GR3020355T3 (en) Aminosulfonyl urea acat inhibitors
PL283722A1 (en) Method for manufacturing phenylhydrazones
HUT77868A (hu) Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
MA26606A1 (fr) Derives de 5-desoxycytidine, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation.